Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18206813 | 1.00 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7361092 | 1.00 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL13647345 | 0.96 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL18206330 | 0.83 | ALOX15 (0.37) | TSHRSMN1; SMN2LMNA | |
| SCHEMBL18206329 | 0.83 | ALOX15 (0.37) | TSHRSMN1; SMN2LMNA | |
| SCHEMBL23397693 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL18206913 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL18219224 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL18206911 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL18206904 | 0.82 | MMP1 (0.33) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-5015641-A | Dipeptide for vision defects | ANDREWS DAVID R (US) | 1991-05-14 | — | — | US | disclosed |
| US-4885293-A | CARBOXYALKYL DIPEPTIDES | SCHERING CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0195817-B1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4826816-A | Antihypertensive compounds | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0236307-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS. | SCHERING CORP (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| WO-1987001707-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4634698-A | TOPICAL HYPOTENSIVES | SCHERING CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0195817-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SCHERING CORP (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| WO-1986001803-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
| US-4556655-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | TSHR 4761/4885CHRM2 367/4885CHRM4 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.